ClinicalTrials.gg
CompletedNCT01026233Updated Dec 12, 2014

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

A Phase 1 interventional study of brentuximab vedotin in Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic and Lymphoma, Non-Hodgkin, sponsored by Seagen Inc.. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-12.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
40th of 80
52 · median 52
Started
2010
with 2 others
Phase 1
12 of 80
none open now
Registered
5th of 80
by date
Lead sponsor
12 of 80
Seagen Inc.

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 40th largest by enrollment, is one of 3 that started in 2010, is one of 12 in phase 1, and was the 5th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.

03

Conditions studied

  • Disease, Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, Non-Hodgkin

Keywords

  • Antibodies, Monoclonal
  • Antibody-Drug Conjugate
  • Antigens, CD30
  • Disease, Hodgkin
  • Drug Therapy
  • Hematologic Diseases
  • Immunotherapy
  • Lymphoma
  • monomethylauristatin E
  • Lymphoma, Large-Cell, Anaplastic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CD30-positive
  • Adequate organ function
  • performance status \<2

Exclusion criteria

Exclusion Criteria:

  • Cardiac abnormalities (abnormal rhythm, history of significant cardiac event)
  • Current diagnosis of primary cutaneous ALCL
  • Acute or chronic
  • Prior hematopoietic stem cell transplant within specified timeframe
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    1

    brentuximab vedotin

    Drug: brentuximab vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. QTc interval

    Time frame: 2-4 days postdose

Secondary outcomes

  1. ECG parameters

    Time frame: 2-4 days postdose

  2. Blood MMAE levels

    Time frame: Through 4 days postdose

  3. Incidence of proarrhythmic adverse events

    Time frame: Through 1 month following last dose

  4. Incidence of adverse events and laboratory abnormalities

    Time frame: Through 1 month following last dose

07

Study locations

9 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • University of Miami Hospital and Clinics, Miller School of Medicine
    Miami, Florida 33136, United States
  • Cardinal Bernardin Cancer Center / Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • New York University Cancer Institute
    New York, New York 10016, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • University Hospital of Cologne
    Koln, 50924, Germany
08

References and documents

Publications

  • Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder NN, Engert A. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30. PubMed 23719719 ↗
  • Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jager U, Bangard C, Boll B, von Bergwelt Baildon M, Theurich S, Borchmann P, Engert A. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012 Aug 16;120(7):1470-2. doi: 10.1182/blood-2012-05-430918. Epub 2012 Jul 11. Erratum In: Blood. 2014 Aug 14;124(7):1201. PubMed 22786877 ↗
  • Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012 Jul 19;120(3):560-8. doi: 10.1182/blood-2011-12-397893. Epub 2012 Apr 17. PubMed 22510871 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Aug 2010 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2009
First posted
Dec 4, 2009
Start
Jan 2010
Primary completionActual
Aug 2010
CompletionActual
Aug 2011
Last update
Dec 12, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01026233
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Dec 4, 2009
Start date
Jan 2010
Primary completion
Aug 2010
Completion
Aug 2011
Last update
Dec 12, 2014

Study contacts

Naomi Hunder, MD
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion